Glycans and glycosylation of platelets: Current concepts and implications for transfusion

Current Opinion in Hematology

Volumn 15, Issue 6, 2008, Pages 606-611

  Sørensen, Anne Louise ^a   Hoffmeister, Karin M ^b   Wandall, Hans H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Clearance; Cold storage; Glycans; Glycosyltransferase; Platelets

Indexed keywords

BETA N ACETYLGLUCOSAMINE; CARBOHYDRATE; GLYCAN; GLYCOPROTEIN; LECTIN RECEPTOR; N ACETYLGLUCOSAMINE; UNCLASSIFIED DRUG;

BACTEREMIA; BLOOD COMPONENT; BLOOD GROUP INCOMPATIBILITY; CARBOHYDRATE METABOLISM; COMBINATORIAL CHEMISTRY; FREEZING; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; INFECTION COMPLICATION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ROOM TEMPERATURE; SEPSIS; THERAPY EFFECT; THROMBOCYTE LIFESPAN; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION;

BLOOD PLATELETS; BLOOD PRESERVATION; COLD TEMPERATURE; GLYCOSYLATION; HUMANS; PLATELET TRANSFUSION; POLYSACCHARIDES;

EID: 55149089839     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328313e3bd     Document Type: Review

References (67)

1. Gottschall JL, Rzad L, Aster RH. Studies of the minimum temperature at which human platelets can be stored with full maintenance of viability. Transfusion 1986; 26:460-462.
2. Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability: deleterious effect of refrigerated storage. N Engl J Med 1969; 280:1094-1098.
3. Slichter SJ, Harker LA. Preparation and storage of platelet concentrates. II. Storage variables influencing platelet viability and function. Br J Haematol 1976; 34:403-419.
4. Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003; 112:87-97.
5. Italiano JE Jr, Bergmeier W, Tiwari S, et al. Mechanisms and implications of platelet discoid shape. Blood 2003; 101:4789-4796.
6. Valeri CR, Ragno G, Marks PW, et al. Effect of thrombopoietin alone and a combination of cytochalasin B and ethylene glycol bis(beta-aminoethyl ether) N,N′-tetraacetic acid-AM on the survival and function of autologous baboon platelets stored at 4 degrees C for as long as 5 days. Transfusion 2004; 44:865-870.
7. Josefsson EC, Gebhard HH, Stossel TP, et al. The macrophage alphaMbeta2 integrin alphaM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem 2005; 280:18025-18032.
8. Hoffmeister KM, Josefsson EC, Isaac NA, et al. Glycosylation restores survival of chilled blood platelets. Science 2003; 301:1531-1534.
9. Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007; 47:1134-1142. This report summarizes the current incidence of septic complications after introduction of bacterial screening of apheresis platelets, based on more than one million donations. It is concluded that bacterial detection only reduces the risk of septic reactions with approximately 50%, and that the residual risk mainly is related to transfusion of old platelets.
10. Blajchman MA, Beckers EA, Dickmeiss E, et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005; 19:259-272.
11. Nussbaumer W, Allersdorfer D, Grabmer C, et al. Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion 2007; 47:1125-1133.
12. Pelletier JP, Transue S, Snyder EL Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006; 19:205-242.
13. Ramirez-Arcos S, Jenkins C, Dion J, et al. Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007; 47:421-429.
14. Kaufman RM. Platelets: testing, dosing and the storage lesion-recent advances. Hematology Am Soc Hematol Educ Program 2006; 492-496.
15. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004; 18:11-24.
16. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008; 22:1-34.
17. Cauwenberghs S, van Pampus E, Curvers J, et al. Hemostatic and signaling functions of transfused platelets. Transfus Med Rev 2007; 21:287-294. This paper provides a comprehensive review of the functional alterations in stored platelets and their possible consequences for transfusion therapy.
18. Maurer-Spurej E, Chipperfield K. Past and future approaches to assess the quality of platelets for transfusion. Transfus Med Rev 2007; 21:295-306.
19. Rock G, Figueredo A. Metabolic changes during platelet storage. Transfusion 1976; 16:571-579.
20. Slichter SJ. In vitro measurements of platelet concentrates stored at 4 and 22 degree C: correlation with posttransfusion platelet viability and function. Vox Sang 1981; 40 (Suppl 1):72-86.
21. Babic AM, Josefsson EC, Bergmeier W, et al. In vitro function and phagocytosis of galactosylated platelet concentrates after long-term refrigeration. Transfusion 2007; 47:442-451.
22. Hornsey VS, Drummond O, McMillan L, et al. Cold storage of pooled, buffy-coat-derived, leucoreduced platelets in plasma. Vox Sang 2008; 95:26-32.
23. Snyder EL, Hezzey A, Katz AJ, Bock J. Occurrence of the release reaction during preparation and storage of platelet concentrates. Vox Sang 1981; 41:172-177.
24. Perrotta PL, Perrotta CL, Snyder EL. Apoptotic activity in stored human platelets. Transfusion 2003; 43:526-535.
25. Kaufman RM. Uncommon cold: could 4 degrees C storage improve platelet function? Transfusion 2005; 45:1407-1412. 26 Choi JW, Pai SH. Influence of storage temperature on the responsiveness of human platelets to agonists. Ann Clin Lab Sci 2003; 33:79-85.
26. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N- acetylglucosamine on nucleocytoplasmic proteins. Nature 2007; 446:1017-1022.
27. Wandall HH, Sorensen AL, Patel S, et al. Megakaryocytes package and deliver Golgi-associated glycosyltransferases into platelets and to platelet surfaces using dense granules. Blood 2005; 106:470A-1470A.
28. Varki A. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature 2007; 446:1023-1029.
29. Sackstein R, Merzaban JS, Cain DW, et al. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14:181-187. This paper elegantly demonstrates how fucosylation of the CD44 glycoform expressed on mesenchymal stem cells, creating the sialyl Lewis X epitope that selectively binds E-selectins and L-selectins, can be used to direct their migration to the correct anatomical department. Glycoengineering of cell membrane proteins is proposed as a general tool to programme cell trafficking.
30. Dube DH, Bertozzi CR. Glycans in cancer and inflammation: potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005; 4:477-488.
31. Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5:526-542.
32. Cooling L. ABO and platelet transfusion therapy, Immunohematology 2007; 23:20-33.
33. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26:732-743.
34. Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70:23-30.
35. Jimenez TM, Patel SB, Pineda AA, et al. Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility. Transfusion 2003; 43:328-334.
36. Carr R, Hutton JL, Jenkins JA, et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990; 75:408-413.
37. American Association of Blood Banks. Technical manual. 14th ed. Bethesda, MD: AABB; 2002.
38. Liu QP, Sulzenbacher G, Yuan H, et al. Bacterial glycosidases for the production of universal red blood cells. Nat Biotechnol 2007; 25:454-464. This elegant study describes two bacterial glycosidase gene families that provide enzymes capable of efficient removal of A and B antigens from the surface of RBCs at neutral pH and with low consumption of recombinant enzymes.
39. Wandall HH, Hoffmeister KM, Sorensen AL, et al. Galactosylation does not prevent the rapid clearance of long-term, 4 degrees C-stored platelets. Blood 2008; 111:3249-3256. This paper describes the results of a clinical feasibility trial showing that galactosylation does not prevent the clearance of human platelets stored for 48 h at 4°C. Moreover, it is shown that galactosylated murine platelets stored under the same conditions are cleared rapidly.
40. Rumjantseva V, Josefsson EC, Wandall H, et al. Hepatocytes ingest long term refrigerated platelets: a novel platelet clearance mechanism. Blood 2006; 108:438A-439A.
41. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51:531-554.
42. Weigel PH, Yik JH. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta 2002; 1572:341-363.
43. Reimers HJ, Greenberg J, Cazenave JP, et al. Experimental modification of platelet survival. Adv Exp Med Biol 1977; 82:231-233.
44. Steiner M, Vancura S. Asymmetrical loss of sialic acid from membrane glycoproteins during platelet aging. Thromb Res 1985; 40:465-471.
45. Greenberg J, Packham MA, Cazenave JP, et al. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 1975; 32:476-484.
46. Kotze HF, van Wyk V, Badenhorst PN, et al. Influence of platelet membrane sialic acid and platelet-associated IgG on ageing and sequestration of blood platelets in baboons. Thromb Haemost 1993; 70:676-680.
47. Elites LG, Ditto D, Levy GG, et al. Sialyltransferase STSGal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci USA 2002; 99:10042-10047.
48. Soerensen AL, Wandall HH, Patel S, et al. Platelets lacking sialic acid clear rapidly from the circulation due to ingestion by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2006; 108:438A-1438A.
49. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008; 14:648-655. An excellent study demonstrating that desialylation of platelets and vWf causes their clearance from the circulation via binding to the ASGPR. This pathway is suggested to operate under pathological conditions, modifying the severity of sepsis caused by certain bacterial species.
50. Tribulatti MV, Mucci J, Van Rooijen N, et al. The trans-sialidase from Trypanosoma cruzi induces thrombocytopenia during acute Chagas' disease by reducing the platelet sialic acid contents. Infect Immun 2005; 73:201-207.
51. Handin RI, Valeri CR. Improved viability of previously frozen platelets. Blood 1972; 40:509-513.
52. Valeri CR, Feingold H, Marchionni LD. A simple method for freezing human platelets using 6% dimethylsulfoxide and storage at -8O°C. Blood 1974; 43:131-136.
53. Khuri SF, Healey N, MacGregor H, et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 117:172-183; discussion 183-184.
54. Valeri CR. Hemostatic effectiveness of liquid-preserved and previously frozen human platelets. N Engl J Med 1974; 290:353-358.
55. Connor J, Currie LM, Allan H, Livesey SA. Recovery of in vitro functional activity of platelet concentrates stored at 4 degrees C and treated with second-messenger effectors. Transfusion 1996; 36:691-698.
56. Currie LM, Harper JR, Allan H, Connor J. Inhibition of cytokine accumulation and bacterial growth during storage of platelet concentrates at 4 degrees C with retention of in vitro functional activity. Transfusion 1997; 37:18-24.
57. Rivera J, Lozano ML, Corral J, et al. Quality assessment of platelet concentrates supplemented with second-messenger effectors. Transfusion 1999; 39:135-143.
58. Perez-Ceballos E, Rivera J, Lozano ML, et al. Evaluation of refrigerated platelet concentrates supplemented with low doses of second messenger effectors. Clin Lab Haematol 2004; 26:275-286.
59. Vadhan-Raj S, Kavanagh JJ, Freedman RS, et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 2002; 359:2145-2152.
60. Gousset K, Wolkers WF, Tsvetkova NM, et al. Evidence for a physiological role for membrane rafts in human platelets. J Cell Physiol 2002; 190:117-128.
61. Tablin F, Wolkers WF, Walker NJ, et al. Membrane reorganization during chilling: implications for long-term stabilization of platelets. Cryobiology 2001; 43:114-123.
62. Gousset K, Tsvetkova NM, Crowe JH, Tablin F. Important role of raft aggregation in the signaling events of cold-induced platelet activation. Biochim Biophys Acta 2004; 1660:7-15.
63. Crowe JH, Tablin F, Wolkers WF, et al. Stabilization of membranes in human platelets freeze-dried with trehalose. Chem Phys Lipids 2003; 122:41-52.
64. Sorensen AL, Reis CA, Tarp MA, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006; 16:96-107.
65. Barber AJ, Jamieson GA. Characterization of membrane-bound collagen galactosyltransferase of human blood platelets. Biochim Biophys Acta 1971; 252:546-552.
66. Barber AJ, Jamieson GA. Platelet collagen adhesion characterization of collagen glucosyltransferase of plasma membranes of human blood platelets. Biochim Biophys Acta 1971; 252:533-545.
67. Jamieson GA, Urban CL, Barber AJ. Enzymatic basis for platelet: collagen adhesion as the primary step in haemostasis. Nat New Biol 1971; 234:5-7.